File(s) not publicly available
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy
journal contribution
posted on 2023-06-08, 11:16 authored by F. Cardoso, P. L. Bedard, E. P. Winer, O. Pagani, E. Senkus-Konefka, Lesley FallowfieldLesley Fallowfield, S. Kyriakides, A. Costa, T. Cufer, K. S. AlbainCompared with treatment options for early-stage breast cancer, few data exist regarding the optimal use of chemotherapy for metastatic breast cancer (MBC). The choice of using a combination of cytotoxic chemotherapies vs sequential single agents is controversial. At the 6th European Breast Cancer Conference, the European School of Oncology Metastatic Breast Cancer Task Force convened an open debate on the relative benefits of combination vs sequential therapy. Based on the available data, the Task Force recommends sequential monotherapy as the preferred choice in advanced disease, in the absence of rapid clinical progression, life-threatening visceral metastases, or the need for rapid symptom and/or disease control. Patient- and disease-related factors should be used to choose between combination and sequential single-agent chemotherapy for MBC. Additional research is needed to determine the impact of therapy on patient-rated quality of life and to identify predictive factors that can be used to guide therapy.
History
Publication status
- Published
Journal
Journal of the National Cancer InstituteISSN
0027-8874Publisher
Oxford University PressPublisher URL
Issue
17Volume
101Page range
1174-81Department affiliated with
- Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Publications
Full text available
- No
Peer reviewed?
- Yes
Legacy Posted Date
2012-04-30Usage metrics
Categories
No categories selectedKeywords
Age FactorsAnthracyclines/administration & dosageAntineoplastic Agents/*administration & dosageAntineoplastic Combined Chemotherapy Protocols/administration & dosageBreast Neoplasms/chemistry/*drug therapy/*pathologyComorbidityCongresses as TopicCross-Over StudiesDeoxycytidine/administration & dosage/analogs & derivativesDrug Administration ScheduleEuropeEvidence-Based MedicineFemaleFluorouracil/administration & dosage/analogs & derivativesHumansInternational CooperationKarnofsky Performance StatusMenopause*Patient Selection*Practice Guidelines as Topic/standardsQuality of LifeRandomized Controlled Trials as TopicSeverity of Illness IndexSocioeconomic FactorsTaxoids/administration & dosageTumor MarkersBiological/analysisVinblastine/administration & dosage/analogs & derivatives
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC